Ensuring consistent access to affordable, quality tuberculosis (TB) medications remains a key focus area in global health. There are commodity access problems for first-line TB medicines and second-line TB medicines/multi-‐drug resistant TB medicines. In order to address these access issues, it is important to have a thorough understanding of the current market structure, competitive landscape and product variance. This analysis of the market for different TB medicines includes understanding the dollar value of the each market, examining volumes and types of treatments purchased (including both the formulation strength and secondary package type), and observing existing purchasing trends by country.
